The Interim Report for the 2nd Quarter 2026 for A.P. Møller – Mærsk A/S is hereby enclosed. CEO of A.P. Møller – Mærsk A/S, Vincent Clerc, states: The second quarter was yet another proof point of the new era of heightened volatility we have entered. Strong, broad-based demand from the Far East since 2024 has resulted in significantly more unbalanced trade flows, with volume levels that are challenging landside infrastructure capacity. From ports to inland transportation, we are seeing increased congestion and disruption across multiple geographies. Our global team’s ability to capture opportunities in these difficult markets has enabled us to deliver significant volume and earnings growth across our businesses, leading to the substantial upgrade to our full-year guidance. As markets evolve, we remain focused on helping...

All key markets and main segments returned to growth in Q2, delivering positive adjusted organic growth. Major investment programmes have now largely been completed, driving greater scalability and automatisation. Solar reconfirms its 2026 EBITDA guidance of DKK 400-480m. CEO Jens Andersen says:“In Q2, all our key markets and main segments returned to growth, resulting in positive adjusted organic growth across the group. EBITDA was on par with expectations, impacted by one-off costs of DKK 38m. While trading conditions improved during the second quarter, H1 revenue and EBITDA remained at the lower end of our expected range, primarily reflecting the impact of the severe winter conditions in Q1, particularly in Denmark and Norway. We also reached important operational milestones during the quarter. Our new logistics centre in Kumla,...

Portfolio expansion and improving asset quality continued to support the Group’s profitable performance Fee income more than doubled year-on-year, increasing its contribution to the Group’s overall revenue mix Multitude completed the acquisition of Sortter Oy, demonstrating execution of the Group’s tri-pillar growth strategy and adding an incremental fee income stream On track to deliver FY2026 net profit guidanceZug, 13 August 2026 – Multitude AG, a listed European FinTech company offering digital lending and online banking services to consumers, SMEs, and institutional clients (“Multitude”, the “Company” or the “Group”), published its H1 2026 results for the period ending 30 June 2026 today. Multitude Group Results Group revenue amounted to EUR 126.9 million (H1 2025: EUR 133.4 million), with interest income amounting...

DEMIRE raises its guidance for 2026 following better-than-expected business performanceRental income declined by 17.11 per cent to EUR 23.0 million following property sales FFO I (after taxes, before minority interests and interest on shareholder loans) amounted to EUR 2.0 million (previous year: EUR 5.0 million) 2026 guidance revised upwards: rental income expected at EUR 42.5–44.5 million (previously: EUR 41.5–43.5 million) and FFO I at EUR 0.5–2.5 million (previously: EUR -1.0–1.0 million)Langen, 13 August 2026.  DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) has performed better than expected in the first half of 2026 and is therefore raising its guidance for the full year. Despite a decline in rental income, as expected, due to ongoing property sales, the company achieved positive FFO I of EUR 2.0 million and...

Company announcement No. 50/2026                                                  13 August 2026 Netcompany – Q2 2026 company announcement Continued strong growth – AI adoption accelerating SummaryOrganic revenue grew by 17.3% (constant 17.1%) to DKK 2,010.8m in Q2 2026. Reported revenue grew by 43.3% in Q2 2026, of which 26.1 percentage points were non-organic related to Netcompany Banking Services. Organic adjusted EBITDA was DKK 289.6m in Q2 2026, yielding an organic adjusted EBITDA margin of 14.4%. Reported adjusted EBITDA increased 47.1% to DKK 324.5m in Q2 2026, yielding an adjusted EBITDA margin of 13.2%. Netcompany Banking Services impacted the margin negatively by 1.2 percentage points in the quarter.   Average workforce increased to 9,895 FTEs. Free cash flow in Q2 2026 was DKK 41.2m. Debt leverage was 2.3x. Financial...

Marimekko Corporation, Half-year Financial Report, 13 August 2026 at 8.00 a.m. EEST HALF-YEAR FINANCIAL REPORT OF MARIMEKKO, 1 Jan–30 June 2026: Marimekko’s Q2 net sales nearly at previous year’s record level, driven by strong growth in APAC; operating profit behind comparison period. Full year guidance unchanged. This release is a summary of Marimekko’s half-year financial report for the January–June period of 2026. The complete report is attached to this release as a pdf file and it is also available on the company’s website at company.marimekko.com under Releases & publications. The second quarter in briefMarimekko’s net sales in the second quarter were nearly at the record level of the comparison period amounting to EUR 43.9 million (44.5). Net sales were weakened by a decrease in retail sales in Finland. On the...

Total product sales of €64.0 millionIn-line with expectations; full-year guidance of €135 -150 million reaffirmedSolid cash position of €121.5 million as of end June 2026Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyondRegulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2  Pfizer remains optimistic about obtaining registration for the vaccine candidate3Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year ended June 30, 2026, provided key corporate updates, and reaffirmed...

Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy.Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results, demonstrating double-digit weight loss with a tolerability profile largely comparable to placebo, supporting its potential to redefine the weight management experience for people living with obesity or overweight. Boehringer Ingelheim presented positive results from the SYNCHRONIZETM-1 and SYNCHRONIZETM-MASLD Phase 3 trials with survodutide, supporting its potential as a differentiated treatment option for people living with obesity or overweight...